# A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

> **NCT03181126** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 69 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia (ALL)
- Lymphoblastic Lymphoma

## Interventions

- **DRUG:** Navitoclax
- **DRUG:** Chemotherapy
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03181126
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2020-11-11
- **Final completion:** 2020-11-14
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2021-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03181126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03181126, "A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03181126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*